Monica Sircar, MD
Internal Medicine · Cambridge
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 18 years
- Harvard Medical School, 2008
Offices
1 location · President and Fellows of Harvard College · 94 clinicians in this group
Looking this up.
Hospitals listed: Mount Auburn Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Sircar’s office at (617) 496-8700 to ask if they take your plan before you enroll.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 86.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Mount Auburn HospitalCambridge, MAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Beth Israel Lahey Health, which runs 10 hospitalsPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.539, Oct 2024 – Sep 2025
See every measure and the patient survey for Mount Auburn Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.539 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.13 to 2.14) · 856 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.74 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 186.93 (131.52 to 242.33) · 45 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 81 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 95 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 197 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 471 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.3 · 576 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 177 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 2,322 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.32 (0.11 to 0.52) · 5,943 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.06 to 0.46) · 5,901 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.88 (1.67 to 6.08) · 1,095 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.45 (0 to 3.07) · 524 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.15 (0.59 to 3.7) · 1,055 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.31 (5.02 to 19.6) · 524 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.59 (4.74 to 12.45) · 509 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.02 (0.52 to 3.52) · 209 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.91) · 5,084 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 126 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.738 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.667 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.353 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.4 · 213 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.3 · 550 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 23 · 204 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 11.4 · 505 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.3 · 580 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18 · 631 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.3 to 7.6) · 124 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.8 to 14.9) · 124 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 108 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 87 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.9 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.2 (9.5 to 15.5) · 2,246 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 624 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,714 patients answered, 25% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$37,512
Medicare paid this office $37,512 for 89 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 54 | $15,295 | $139 |
| Return visit (30+ min) | 48 | $6,199 | $94 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 17 | $4,646 | $273 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,951 | $108 |
| Short return visit (20+ min) | 25 | $1,705 | $59 |
See all 10 services
| Long return visit (40+ min) | 54 | $15,295 | $139 |
| Return visit (30+ min) | 48 | $6,199 | $94 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 17 | $4,646 | $273 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,951 | $108 |
| Short return visit (20+ min) | 25 | $1,705 | $59 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $1,378 | $81 |
| Influenza vaccine split virus, preservative free | 12 | $982 | $82 |
| Admn sarscov2 vacc 1 dose | 11 | $612 | $47 |
| Administration of pneumococcal vaccine | 16 | $565 | $35 |
| Administration of influenza virus vaccine | 12 | $424 | $35 |
Who their Medicare patients are
89 Original Medicare patients in 2024. Average age 79 · Under 65 0% · 85 and older 21% · Women 42% · Health risk score 0.97. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 53% · Atrial fibrillation 21% · Coronary heart disease 16% · Diabetes 13% · Chronic kidney disease 13% · Cancer 13% · Depression 12%.
The office billed $92,305, Medicare allowed $49,706 and paid $37,512; for 358 services of 25 kinds; $7,963 of it was for drugs given in the office and $29,549 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 89 | 358 | 79 | 0.97 | $92,305 | $37,512 |
| 2023 | 79 | 172 | 79 | 0.71 | $47,404 | $18,454 |
| 2022 | 95 | 148 | 69 | 1.18 | $24,422 | $7,099 |
| 2021 | 73 | 173 | 70 | 1.17 | $38,497 | $15,343 |
| 2020 | 75 | 108 | 69 | 1.38 | $22,973 | $7,689 |
| 2019 | 47 | 51 | 66 | 1.73 | $15,482 | $2,270 |
| 2018 | 35 | 38 | 71 | 1.53 | $11,693 | $2,005 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 39 | $8,183 | $149 |
| Return visit (30+ min) | 34 | $4,814 | $109 |
| Short return visit (20+ min) | 24 | $1,901 | $79 |
2022: 2 services
| Short return visit (20+ min) | 59 | $3,592 | $45 |
| Return visit (30+ min) | 29 | $1,586 | $53 |
2021: 4 services
| Long return visit (40+ min) | 50 | $8,648 | $120 |
| Telephone medical discussion with physician, 21-30 minutes | 22 | $2,654 | $72 |
| Return visit (30+ min) | 16 | $1,442 | $80 |
| Short return visit (20+ min) | 14 | $824 | $59 |
2020: 2 services
| Telephone medical discussion with physician, 21-30 minutes | 43 | $3,525 | $65 |
| Return visit (30+ min) | 17 | $1,308 | $69 |
2019: 2 services
| Return visit (30+ min) | 19 | $1,281 | $61 |
| Short return visit | 12 | $197 | $16 |
2018: 1 service
| Return visit (30+ min) | 13 | $876 | $63 |
Medicaid work
$5,362 in 2022
Medicaid paid $5,362 for 126 billed services this clinician did in 2022, up to 27 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 114 | $4,565 |
| Return visit (30+ min) | 12 | $798 |
| 2022 | 126 | 2 | 27 | $5,362 |
Drugs they prescribed that Part D paid
$74,568
Pharmacies billed $74,568 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
703 generic and 71 brand-name prescriptions · $74,568 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 15 | $23,072 | $1,538 |
| Atorvastatin | 98 | $2,837 | $29 |
| Tamsulosin | 58 | $1,103 | $19 |
| Rosuvastatin | 48 | $837 | $17 |
| Metoprolol | 24 | $704 | $29 |
See all 19 drugs
| Eliquis | 15 | $23,072 | $1,538 |
| Atorvastatin | 98 | $2,837 | $29 |
| Tamsulosin | 58 | $1,103 | $19 |
| Rosuvastatin | 48 | $837 | $17 |
| Metoprolol | 24 | $704 | $29 |
| Synthroid | 13 | $584 | $45 |
| Simvastatin | 31 | $464 | $15 |
| Losartan | 26 | $382 | $15 |
| Losartan-Hydrochlorothiazide | 16 | $379 | $24 |
| Levothyroxine | 20 | $326 | $16 |
| Gabapentin | 20 | $247 | $12 |
| Allopurinol | 39 | $222 | $6 |
| Pravastatin | 13 | $213 | $16 |
| Amlodipine Besylate | 43 | $179 | $4 |
| Atenolol | 11 | $113 | $10 |
| Lisinopril-Hydrochlorothiazide | 11 | $102 | $9 |
| Lisinopril | 25 | $86 | $3 |
| Furosemide | 14 | $41 | $3 |
| Hydrochlorothiazide | 14 | $28 | $2 |
Year by year
| 2024 | 786 | 100 | None | 9% | $74,568 |
| 2023 | 498 | 135 | 2% (11) | None | $54,020 |
| 2022 | 1,276 | 163 | 1% (18) | 21% | $195,374 |
| 2021 | 800 | 145 | 2% (19) | 19% | $116,898 |
| 2020 | 209 | 86 | 8% (16) | None | $12,578 |
| 2019 | 28 | 18 | 0% (0) | None | $1,069 |
| 2018 | 37 | 21 | 0% (0) | 38% | $1,637 |
| 2017 | 43 | 21 | None | 28% | $6,581 |
| 2016 | 53 | 16 | 0% (0) | None | $514 |
| 2015 | 21 | 11 | 0% (0) | None | $198 |
| 2014 | 31 | None | 0% (0) | None | $435 |
| 2013 | 32 | 14 | None | None | $578 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Atorvastatin | 54 | $1,979 | $37 |
| Simvastatin | 29 | $613 | $21 |
| Losartan | 20 | $556 | $28 |
| Tamsulosin | 22 | $521 | $24 |
| Rosuvastatin | 25 | $517 | $21 |
| Metoprolol | 12 | $448 | $37 |
| Amlodipine Besylate | 16 | $349 | $22 |
| Metformin Hcl Er | 17 | $315 | $19 |
| Levothyroxine | 12 | $266 | $22 |
| Metformin | 14 | $229 | $16 |
| Gabapentin | 14 | $221 | $16 |
| Tramadol | 11 | $191 | $17 |
| Hydrochlorothiazide | 11 | $82 | $7 |
2022: 28 drugs
| Trulicity | 48 | $52,508 | $1,094 |
| Jardiance | 34 | $29,471 | $867 |
| Lantus Solostar | 29 | $15,594 | $538 |
| Farxiga | 21 | $11,420 | $544 |
| Advair Hfa | 12 | $4,796 | $400 |
| Atorvastatin | 116 | $1,493 | $13 |
| Albuterol Sulfate Hfa | 27 | $1,107 | $41 |
| Metformin | 69 | $832 | $12 |
| Metoprolol | 20 | $799 | $40 |
| Lisinopril | 60 | $670 | $11 |
| Nifedipine Er | 12 | $629 | $52 |
| Amlodipine Besylate | 54 | $621 | $11 |
| Omeprazole | 34 | $597 | $18 |
| Rosuvastatin | 27 | $597 | $22 |
| Metformin Hcl Er | 42 | $576 | $14 |
| Levothyroxine | 30 | $570 | $19 |
| Fluticasone Propionate | 36 | $548 | $15 |
| Losartan | 36 | $492 | $14 |
| Famotidine | 29 | $402 | $14 |
| Pantoprazole | 16 | $372 | $23 |
| Pravastatin | 12 | $284 | $24 |
| Allopurinol | 14 | $211 | $15 |
| Metoprolol | 19 | $184 | $10 |
| Simvastatin | 28 | $181 | $6 |
| Gabapentin | 13 | $167 | $13 |
| Hydrochlorothiazide | 25 | $143 | $6 |
| Citalopram Hbr | 14 | $117 | $8 |
| Tramadol | 14 | $70 | $5 |
2021: 17 drugs
| Trulicity | 30 | $33,452 | $1,115 |
| Metoprolol | 41 | $933 | $23 |
| Levothyroxine | 40 | $797 | $20 |
| Atorvastatin | 57 | $741 | $13 |
| Nifedipine Er | 16 | $568 | $36 |
| Omeprazole | 43 | $500 | $12 |
| Losartan | 18 | $335 | $19 |
| Lisinopril | 33 | $324 | $10 |
| Amlodipine Besylate | 37 | $316 | $9 |
| Metformin | 37 | $268 | $7 |
| Metformin Hcl Er | 12 | $149 | $12 |
| Metoprolol | 15 | $128 | $9 |
| Fluticasone Propionate | 13 | $120 | $9 |
| Hydrochlorothiazide | 15 | $119 | $8 |
| Tramadol | 11 | $107 | $10 |
| Simvastatin | 13 | $89 | $7 |
| Trazodone | 11 | $59 | $5 |
2020: 2 drugs
| Levothyroxine | 21 | $546 | $26 |
| Atorvastatin | 12 | $140 | $12 |
2016: 2 drugs
| Amlodipine Besylate | 18 | $63 | $3 |
| Lisinopril | 12 | $15 | $1 |
Money from drug and device companies
$117 in 2025
A payment is not proof that care is biased.
| Novo Nordisk | Wegovy | $82 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | None | $35 | 1 payment
|
See all 2 published payments
| Novo Nordisk | Meals · 2025-11-06 | Wegovy | $82 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-31 | None | $35 |
Professional record
- NPI
- 1548421696
- Licence
- MA 258942
- Trained
- Harvard Medical School, 2008 · 18 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X); Student in a training program (390200000X)
- Mailing address
- 75 Mount Auburn St, Cambridge, MA, 02138
- NPI first listed
- 2008-06-20
- NPI last updated
- 2024-11-06
- NPI record certified
- 2024-11-06
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 55 Fruit St, Boston, MA, 02114 · 1493 Cambridge St, Cambridge, MA, 02139 · 300 Pasteur Dr # S101, Stanford, CA, 94305